Angeliq Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Angeliq (Drospirenone/Estradiol) Supply and Availability in 2026

If your patients are reporting difficulty filling Angeliq (Drospirenone/Estradiol) prescriptions, you're seeing a pattern that's become increasingly common. While Angeliq is not on the FDA's formal Drug Shortage Database, the practical reality is that many pharmacies — particularly large chain locations — do not routinely stock it.

This briefing provides an up-to-date overview of Angeliq's supply status, cost landscape, prescribing considerations, and actionable steps you can take to support patients who rely on this medication.

Timeline and Current Status

Angeliq has been marketed in the United States since FDA approval in September 2005. Key milestones relevant to the current availability picture:

• 2005: FDA approves Angeliq 0.5 mg DRSP/1 mg E2 (Bayer HealthCare Pharmaceuticals)
• 2012: FDA approves the low-dose formulation — 0.25 mg DRSP/0.5 mg E2
• October 2025: FDA approves generic Angeliq 0.5 mg/1 mg (Novast Labs)
• Early 2026: Generic not yet commercially available; brand remains sole supply source

Angeliq has never been subject to a formal FDA-reported shortage. However, its status as a niche, single-manufacturer brand-name product creates inconsistent availability that functionally resembles a shortage for affected patients.

Prescribing Implications

When prescribing Angeliq, consider the following factors that may affect your patient's ability to fill the prescription:

Pharmacy Stocking

Most chain pharmacies use automated inventory systems that base stocking decisions on recent prescription volume. Angeliq's limited patient base means many locations don't carry it. Patients may need to:

• Request a special order (1–3 business day turnaround)
• Transfer to an independent pharmacy with flexible ordering capabilities
• Use a mail-order or specialty pharmacy

Insurance Coverage

Angeliq is frequently classified as a Tier 3 (preferred brand) or non-preferred brand on commercial formularies. Common requirements include:

• Prior authorization — documenting medical necessity
• Step therapy — trial and failure of a generic combination HRT (typically Activella/generic estradiol-norethindrone acetate) before Angeliq approval
• Quantity limits — some plans limit to a 30-day supply per fill

Medicare Part D coverage varies by plan. Many Part D plans cover Angeliq but with higher cost-sharing. Be prepared to submit appeals or formulary exception requests when clinically warranted.

Hyperkalemia Monitoring

Drospirenone's anti-mineralocorticoid activity warrants attention in patients taking concomitant medications that raise potassium. Per the prescribing information, consider monitoring serum potassium during the first treatment cycle in patients who take:

• ACE inhibitors or ARBs
• Potassium-sparing diuretics
• NSAIDs chronically
• Potassium supplements
• Strong CYP3A4 inhibitors (which may increase drospirenone levels)

Angeliq is contraindicated in patients with renal impairment, hepatic impairment, or adrenal insufficiency. For a complete interaction profile, see Angeliq drug interactions: what to avoid.

The Availability Picture

The current availability constraints stem from several interconnected factors:

1. Single manufacturer: Bayer is the sole source. No second-source manufacturer exists yet.
2. Approved generic not launched: Novast Labs received FDA approval for generic Drospirenone/Estradiol 0.5 mg/1 mg in October 2025 but has not yet brought the product to market.
3. Low stocking priority: Wholesalers and pharmacies allocate shelf space based on demand volume. Angeliq's niche status means inconsistent stocking.
4. Cost-driven demand suppression: At $186–$242/month cash price, insurance friction reduces prescriptions filled, further depressing demand signals.

Cost and Access Considerations

Understanding the cost landscape helps when counseling patients and completing prior authorization paperwork:

• Average retail (cash) price: ~$234/month (28 tablets)
• With GoodRx coupon: ~$186/month
• With SingleCare coupon: ~$184/month
• Bayer Savings Card: Reduces copay for commercially insured patients — savingscard.bayer.com
• Bayer US Patient Assistance Foundation: Provides Angeliq at no cost to eligible patients with financial hardship. Application submitted by the provider's office; 3-month supply shipped to clinic — patientassistance.bayer.us

For comparison, generic estradiol/norethindrone acetate (Activella equivalent) costs approximately $15–$30/month with a discount card.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a provider-facing tool that checks real-time pharmacy availability. You or your staff can search for Angeliq by zip code to identify which pharmacies near your patient currently have stock. This can be integrated into your prescribing workflow to avoid sending patients to pharmacies that can't fill the script.

Bayer Patient Assistance Foundation

For uninsured or underinsured patients who qualify, the Bayer US Patient Assistance Foundation can provide Angeliq at no cost. The application process requires a provider signature. Visit patientassistance.bayer.us for enrollment details.

Specialty and Mail-Order Pharmacies

If local availability is consistently poor, consider directing patients to mail-order pharmacies, which typically maintain larger inventories of brand-name medications. Many insurance plans incentivize mail-order with lower copays for 90-day supplies.

Therapeutic Alternatives

When Angeliq is unavailable or cost-prohibitive, the following combination HRT options may be considered. Each has a distinct progestin component and delivery mechanism:

• Activella (Estradiol 1 mg / Norethindrone Acetate 0.5 mg) — oral, generic available, ~$15–$30/month. Most accessible substitute.
• Prempro (CE 0.625 mg / MPA 2.5 mg) — oral, generic available, ~$20–$50/month. Uses conjugated equine estrogens.
• Climara Pro (Estradiol 0.045 mg/day / Levonorgestrel 0.015 mg/day) — transdermal patch, weekly application. May be preferred for patients with VTE risk factors.
• Bijuva (Estradiol 1 mg / Progesterone 100 mg) — oral, uses micronized bioidentical progesterone. Brand only, ~$150–$300/month.

Note: Drospirenone's unique anti-mineralocorticoid and anti-androgenic properties are not replicated by the progestin components in these alternatives. For patients who specifically benefit from these properties (e.g., fluid retention management, mild blood pressure effects), switching may require additional counseling.

Looking Ahead

The most significant near-term development is the potential commercial launch of generic Angeliq by Novast Labs. If and when the generic reaches pharmacies, it should meaningfully improve both availability and affordability. However, no commercial launch date has been announced as of April 2026.

In the meantime, proactive prescribing practices — checking availability before writing, considering pharmacy type, and having alternative HRT plans ready — will help your patients avoid treatment gaps.

Final Thoughts

Angeliq occupies a unique niche in the HRT landscape. Its drospirenone component offers genuine pharmacological advantages for some patients, but its single-manufacturer status and cost barriers create ongoing access challenges. By leveraging tools like Medfinder for providers, staying informed about the generic pipeline, and maintaining familiarity with therapeutic alternatives, you can help your patients navigate these challenges effectively.

For patient-facing resources to share, consider: How to find Angeliq in stock near you and How to save money on Angeliq.